|Publication number||US5171264 A|
|Application number||US 07/486,153|
|Publication date||Dec 15, 1992|
|Filing date||Feb 28, 1990|
|Priority date||Feb 28, 1990|
|Also published as||CA2074730A1, CA2074730C, DE69102062D1, DE69102062T2, EP0516749A1, EP0516749B1, WO1991012886A1|
|Publication number||07486153, 486153, US 5171264 A, US 5171264A, US-A-5171264, US5171264 A, US5171264A|
|Inventors||Edward W. Merrill|
|Original Assignee||Massachusetts Institute Of Technology|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (15), Non-Patent Citations (15), Referenced by (155), Classifications (58), Legal Events (7)|
|External Links: USPTO, USPTO Assignment, Espacenet|
Polyethylene oxide (PEO) is an important biomaterial because it is non-thrombogenic, i.e., it does not adsorb proteins of the intrinsic clotting system nor of the platelet membrane. However, when PEO is combined with other molecules at the surface, thrombogenicity may be enhanced. Okkema, A. Z., J. Biomat. Sci. 1:43-62 (1989). Thus, it is essential that no other molecular entity besides PEO be accessible to proteins. It has been widely studied as a blood-contacting biomaterial in various forms: in segmented polyurethane, in block copolymers with styrene or siloxane blocks, end-linked into junctions through isocyanate reactions, as side-chains on acrylate polymers and as hydrogels cross-linked from PEO solutions.
PEO is naturally soluble in water and certain organic solvents. Therefore, in order to render PEO insoluble it must be crosslinked, or end-linked to a support. The manner in which this is accomplished often affects physical and chemical properties of PEO.
Chemical crosslinking of PEO can be employed but the chemical crosslinking agent (e.g., a polyglycidoxypropyl siloxane) may be incorporated into the PEO. This can cause adverse biopolymer reactions, including non-specific binding of proteins and platelet adhesion.
Physically crosslinked PEO produced from polyethylene oxide-polystyrene multiblock polymers or from polyether-urethanes suffers from the presence of the non-PEO material at the surface. Adverse biological reactions caused by the non-PEO material can be avoided if the molecular weight of the PEO is made higher than about 5000. However, such material tends to swell excessively in water and is fragile.
End-linking PEO to supports by various means, so as to leave an available hydroxyl group for attachment of an affinity ligand, for example, is not easily carried out if the molecular weight of the PEO is more than about 1000. Furthermore, complete coverage of a surface by end-linking PEO is very difficult, unless the molecular weight is relatively high (several thousand).
Various forms of PEO have also been widely used as a molecular leash for affinity ligands and enzymes. Golander, C. G. et al., Int. Chem. Congress of Pacific Basin Societies, Abstract No. 253, Honolulu, Hi., Dec. 17-22, 1989; Harris J. M., J. Macromolecular Sci. C25:325-373 (1985); Holmberg, K., Int. Chem. Congress of Pacific Basin Societies, Abstract No. 255, Honolulu, Hi., Dec. 17-22, 1989. Typically, PEO has terminal hydroxyl groups which can be activated for attachment to biopolymers. Most processes for forming PEO biomaterials, however, reduce the hydroxyl content to very low values or zero. In order to produce a crosslinked PEO having a significant concentration of terminal hydroxyls, low molecular weight PEO (2,000 to 10,000) are required but often result in fragile materials. Alternatively, using short PEO side chains on macrometers like polyethylene glycol methacrylate may result in exposure of the methacrylate residues at the surface.
Thus, a need exists for a method of immobilizing PEO to a support surface without detracting from its physical properties and biological compatability. In addition, it would be desirable to provide a material having a high concentration of hydroxyl groups for attachment to biopolymers.
This invention pertains to a method for covalently immobilizing polyethylene oxide star molecules onto a support surface and to hydrogels produced by the method. The PEO star molecules are immobilized in the form of hydrogels using radiation or hydroxyl group activation. The resulting PEO hydrogels have a high concentration of terminal hydroxyl groups which are available for attachment to biospecific affinity ligands or to the support surface itself. As such, the immobilized PEO star molecules can be used as a tool for separating and purifying biological molecules, while greatly reducing or eliminating non-specific binding.
The PEO star molecule hydrogels also have non-thrombogenic properties which make them suitable for applications in which blood contact is required. They are highly biocompatible and have excellent mechanical durability for numerous biomedical applications, including intravenous catheters and implantable vascular prostheses.
FIG. 1a shows a Type I PEO star molecule having a divinyl benzene (DVB) core and PEO chains attached thereto.
FIG. 1b shows a Type II PEO star molecule having a DVB core and PEO chains attached thereto by polystyrene (PS) chains.
FIG. 2 shows overlapping PEO star molecules (Type I) which are crosslinked to each other by electron irradiation.
FIG. 3 shows several PEO star molecules (Type I) covalently attached to a support surface by tresylated hydroxyl groups.
FIG. 4 illustrates the attachment of a biopolymer (IgG) to the surface of immobilized PEO star molecules.
Polyethylene oxide star macromolecules have been previously described by Lutz, P. and P. Rempp, Makromol. Chemie 189:1051 (1988) and Gnanou, Y. et al., Makromol. Chemie 189:2893-2897 (1988), the teachings of which are incorporated by reference herein. The star molecules are synthesized by anionic polymerization from divinyl benzene (DVB), ethylene oxide and optionally styrene. They have a core of divinyl benzene (typically on the order of about 50 angstroms) from which a predetermined number of polyethylene oxide chains or "arms" are grown. The cores however can be of polymeric material other than divinyl benzene. The length of each PEO chain corresponds to its molecular weight and typically range from about 1,000 to about 10,000. Preferably, each star molecule will have from about 6 to about 50 arms. Two variations of PEO star molecules are shown in FIGS. 1A and 1B and are described herein as Type I and Type II, respectively. Type I star molecules contain a plurality of hydroxyl-terminated PEO chains (hydrophilic) that are attached to a hydrophobic DVB core by non-hydrolyzable carbon-carbon bonds. Type II PEO star molecules are of similar composition except that the PEO chains are attached to the DVB core via hydrophobic polystyrene (PS) chains.
The concentration of hydroxy-termini on the PEO arms can be determined in advance by selection of the gross concentration of star molecules and the number of arms carried by the molecule. For example, a star molecule of 100,000 molecular weight with 20 PEO arms has 20 hydroxyls. To obtain comparable hydroxyl concentrations with linear PEO polymers, the molecular weight would have to be lowered to 10,000. However, hydrogels made of cross-linked linear PEO of comparable molecular weights (MW 10,000) are very fragile.
The PEO star molecules can be immobilized or grafted onto a support surface of any geometry (e.g., particles, porous plastic cones, thin plastic film, biomedical device) using ionizing radiation. According to the method, PEO star molecules are dissolved or suspended in an aqueous solution (preferably water) in a concentration sufficient to provide enough star molecules to cover the support surface to desired thickness. Typically, a sufficient concentration will be around 5 to 15 wt/vol %. Type I star molecules form optically clear homogeneous solutions in water, while Type II star molecules form faintly turbid to opaque suspensions, due to the presence of polystyrene. The resulting solution is then deposited onto the support surface, such as by spreading, rotating the support or centrifugation.
The star molecules are then crosslinked together by exposing them to electron beam radiation which results in the formation of a hydrogel network. The term "hydrogel" refers to a broad class of polymeric materials which are swollen extensively in water but which do not dissolve in water. Typically, the solution is exposed to electron radiation in the range of from about 1 to about 6 megarads, most preferably 4 megarads. Gamma radiation can be used as the radiation source but may result in the degradation of the star molecules. Crosslinking occurs randomly between segments of the PEO arms, thus allowing the terminal hydroxyl groups to remain available for subsequent activation, such as coupling affinity ligands to the PEO arms.
FIG. 2 shows several Type I PEO star molecules crosslinked together by electron radiation. The resulting hydrogel layers are of variable thickness but are typically on the order of magnitude of >1 μM. The thickness of the hydrogel layer can be regulated by various techniques, such as doctor-blade spreading on a support web or centrifugal casting in tubes.
An advantage of electron radiation crosslinking is that the crosslinking reaction proceeds very rapidly, at a rate of approximately 1 foot/sec. in the case of web coating. The reaction proceeds by free-radical coupling to produce a pure product. As such, the crosslinking reaction does not alter the chemical composition of the star molecules. Other known cross-linking techniques tend to introduce chemical components which may subsequently affect is biocompatibility. Further, the hydrogel network has a surface for contacting biological materials (e.g. blood) which is essentially PEO chains. As such, the DVB and PS components are inaccessible or not recognizable to these biological molecules.
The resulting hydrogels have significantly greater mechanical strength than hydrogels formed from ordinary linear PEO having the same range of molecular weight as the star (i.e., 100,000 to 300,000). A gel made from 10 wt. % of 100,000 molecular weight linear PEO under identical dosage would have 2 to 10 times lower tensile strength than the network formed from star molecules, and would have only 1/10th the number of hydroxyl groups per unit area of surface. The concentrations of hydroxyl ends obtained by stars would translate to linear polyethylene oxide of around 5,000 mol. wt. or less. Such low molecular weight polymers cannot be crosslinked at all, or form gels of low strength with considerable soluble fraction.
In another embodiment, the star molecules can be covalently immobilized to a support surface by tresylation of the terminal hydroxyl groups. The support surface and star molecules are each pretreated prior to immobilization. As such, the support surface should contain active functional groups for immobilizing tresylated star molecules thereto, such as amino and/or thiol groups. Likewise, the star molecules should be tresylated in an appropriate solvent at pH 10 or above, prior to contacting with the support surface. Tresylation is particularly convenient since the PEO is solvated by media appropriate to tresyl chloride (e.g., dichloromethane, chloroform). This method results in a monolayer coating of the hydrogel over the support surface.
According to this method, an organic solution comprising PEO star molecules is exposed to tresyl chloride, under conditions such as to fix the tresyl groups to hydroxy-termini on the star molecules. The resulting tresylated PEO star molecules are then transferred from the organic solvent to an aqueous solution. The pH of the aqueous solution is then adjusted to about 10 or above, so as to favor reaction with amino and/or thiol groups on the support surface. The pH-adjusted solution is contacted with a pretreated surface support that contains amino and/or thiol groups, under conditions whereby the star molecules become covalently bound in a dense layer to the support surface.
This process is further described below by way of illustration. For example, a Cellophane™ (cellulose containing plasticizers) containing support is placed in a bath of tetrahydrofuran and tresyl chloride. The hydroxyl groups on the surface of the Cellophane™ are then tresylated. Once tresylated, the Cellophane™ is aminated in a water solution of mercaptoethanol amine (pH 10) which results in binding the group --SCH2 CH2 NH2 to the activated hydroxyl groups. Likewise, star molecules are tresylated and then placed into an aqueous buffer (pH 10) containing the aminated Cellophane™. After a period of time (approx. 1 hr), the Cellophane™ is removed from the solution and rinsed to wash off any unbound star molecules. The star molecules become bound to the amino group via the tresylated hydroxyls. FIG. 3 shows several PEO star molecules immobilized on a support surface. The attachment results from the reaction of amino groups on the support surface with tresylated hydroxyls on the star molecules.
The star molecule hydrogels can be covalently bonded onto an appropriate support surface using the method previously described to thereby protect the support from recognition by bipolymers. A monolayer coating of PEO star molecules can be accomplished by attaching one or more PEO arms to the support. The remaining arms remain available for attaching biopolymers or affinity ligands. The PEO-coated support surface can then be exposed to a biopolymer having amino or thiol groups which can couple to available tresylated hydroxyl groups. These available groups function as molecular leashes or tethers for the bipolymer. For example, anti-Protein C antibody can be attached to the star molecules and will be selective for its antigen, Protein C. The PEO monolayer prevents adsorption of the biopolymers onto the support surface and can thereby reduce or eliminate non-specific binding of undesired bipolymers. FIG. 4 demonstrates the use of star molecules for attaching affinity ligands, such as Immunoglobulin G. The symbol represents a covalent linkage between a PEO arm and an amino group on the support: represents a covalent linkage between a PEO arm and an amino or thiol group on IgG; represents an endcapped previously tresylated hydroxyl (e.g., by treatment with mercaptoethanol).
Due to the number of available PEO arms which can accommodate ligands, the hydrogels of this invention can be used to continuously separate, purify and concentrate therapeutic proteins. Processing of the proteins will require cycles of coupling and decoupling of the ligate to affinity ligands bound to the stars.
The affinity surface can be of any geometric shape, such as particles packed in beds, freely moving particles and porous membranes. The hydrogels can be coated onto silica particles. In this case, polyethylene oxide is physically absorbed to the silica surface but cannot be covalently bound unless the silica has been previously modified. Nonetheless, the polyethylene oxide hydrogel forms a shell covering the particle and it thus cannot escape. The hydrogels can also be deposited into pores of ultrahigh molecular weight, high density polyethylene such as Porex™ (Auburn, Ga.), on the surface of Goretex™ e-PTFE (expanded polytetrafluoroethylene) and Mylar™ film.
In most cases, once a PEO hydrogel is coated onto the affinity surface, the terminal hydroxyl groups are activated by tresylation. Preferably, this is accomplished by contacting the hydrogel with tresyl chloride dissolved in an organic solvent, such as dichloromethane. The tresylated PEO star molecules are then placed in buffered aqueous solution containing the affinity ligand which is to be bound. Examples of preferred ligands include antibodies and Fab fragments thereof, Protein A, active polysaccharides, heparin-NH2, anti-Protein C IgG, and the Fab fragment of anti-Protein C IgG.
Following affinity bonding of a specific ligate to its bound ligand, the hydrogel-coated affinity support is washed to remove unbound proteins. Remaining bound proteins are then decoupled by changing the composition of the eluting buffer, for example by changing the ionic strength or the pH (e.g., to pH 10 or above) of the eluting buffer. For example, a 1 M NaCl decoupling solution can be used in the case of antithrombin III bound to heparin. The decoupling results in free ligate in the eluting buffer. The ligate can then be separated from the eluting buffer using known techniques, such as by diafiltration described by Herak and Merrill, Biotech. Prog. 5:9-17 (1989). Separated ligates can then be constructed using known techniques. Examples of some specific ligates include macromolecules, monoclonal antibodies, antigens, viruses and cells (e.g., blood platelets, white blood cells, endothelial cells and other non-blood cells).
In addition to bioseparations, the hydrogels made according to this invention are useful for a variety of biomedical applications, due to their non-thrombogenic properties and excellent mechanical durability. They are suitable for in vivo applications in which blood contact is required, including blood contacting implantable vascular prostheses, angioplastic stents, cardiovascular sutures, metabolic support catheters, angioplastic balloon catheters, artificial hearts and ventricular assist devices. The hydrogels may also be used for ex vivo devices, such as hemadialysis membranes and membranes for extra-corporeal oxygenators.
Additional chemical components can be incorporated into the star hydrogels depending upon the application. In some instances it may be advantageous to incorporate heparin into the hydrogel to further reduce thromogenicity. While heparin can be attached covalently to tresylated hydroxyls on the star molecules, it is also readily incorporated at high concentrations in the hydrogel by simply adding it to the solution of the star before irradiation. In this form it elutes into the blood flow over a significant period of time.
The invention will be further illustrated by the following Example.
Linear PEO and various forms of star molecules having the physical properties described below were electron beam irradiated, at a dose rate of about 0.1 megarad per second, and with a 2 megarad dose per pass under the beam to form hydrogels. Radiation was delivered from a 3 MeV Van de Graaff generator (MIT High Voltage Research Laboratory).
Table 1 presents the apparent swelling ratio q at 25° C. (q=volume of hydrogel equilibrated in water/volume of original mixture irradiated) as a function of radiation dose D in megarad, and as a function of the star type. Two linear PEO samples are included for reference. The concentration of the solution as irradiated in every case was 10.1 wt/vol. % in MilliQ® water. From Table 1 is apparent that the swelling ratio q of hydrogels formed from star molecules is significantly less than for hydrogels from linear PEO types. Furthermore, the high styrene content Type II hydrogels (3103, 3229) exhibit virtually no swelling.
TABLE 1__________________________________________________________________________Swelling Ratios q of 10 wt/vol. % Polymer/WaterAfter Electron Beam Irradiation mol. wt. total % S # arms M PEO M PS D q [OH] μM__________________________________________________________________________Linear PEONominal 300,000 m.w. 4 2.03 0.33 6 1.92 0.35Nominal 100,000 m.w. 4 2.8 0.71 6 2.4 0.83Type I Stars (no styrene)3098 229,000 43 5300 4 1.3 14.63210 142.000 40 3460 4 1.4 20.03224 79,000 8 10,000 6 1.6 6.3Type II Stars3103 190,000 20 16 8000 2000 4 ˜1.0 8.43229 257,000 30 25 6800 3200 4 ˜1.0 9.63385 371,000 2 30 12,000 520 4 1.7 4.7 6 1.6 5.7__________________________________________________________________________ D: dose in megarads Total mol. wt. of stars by light scattering q: Swelling Ratio [OH]: g. equiv. per liter of gel swollen to equilibrium in water at 25° C.
From the results, the random cross-linking of star molecules cannot be expected to lead to networks like those produced from randomly cross-linked linear macromolecules, in which the functionality of the junction φ is necessarily 4. In contrast, the incorporation of stars implies incorporation of junctions of high functionality φ, i.e., φ=# arms. Further, the "junction" is in effect a high modulus poly DVB core, in Type I stars, and an even more complicated entity, i.e., poly DVB with short polystyrene arms, in Type II stars. Thus, the space occupied by the "junction", and the thermodynamically adverse junction-water interaction place the star hydrogel beyond the tenets of the Flory-Huggins theory of swelling of randomly cross-linked networks.
The last column in Table 1 shows the molar hydroxyl content of the gel at equilibrium in water [OH], calculated as: (mols OH/100 g. dry polymer)q-1, wherein the first term is determined as (number of arms/total mol. wt.)·100. Each original solution at 10 wt/vol. % contains 100 g dry polymer per liter. The final wt/vol. % polymer in the gel at equilibrium with water is thus 10/q. This is very important if the star hydrogel is to be deployed as a model biomaterial to which bioactive species are to be grafted. It is desirable to have a high value of [OH] and a low swelling ratio q in order that the biomaterial remain approximately in the shape in which it was cast. Stars 3098 and 3210 as hydrogels provide examples.
In the hydrated state, i.e., in equilibrium with blood plasma, preliminary studies of platelet deposition indicate that the surface of star hydrogel is entirely PEO, that is, the poly DVB core is buried and inaccessible, because of the fact that the Star hydrogel acts as if it were a hydrogel of linear PEO. Crosslinking of these arms is random granting that all PEO arms have approximately the same molecular weight on a given star type as a consequence of the anionic polymerization route. Under an electron beam hydroxyl radicals created from water constitute the principal reagent and therefore the PEO rather than the poly DVB and PS experiences macroradical formation and subsequent coupling. To some degree scission of the arms must occur competitively with cross-linking under radiation. The terminal hydroxyl concentrations [OH] calculated in Table 1 do not take this into account.
Hydrogels containing Type I Stars 3098 or Type II Stars 3385, described above, were examined for biocompatability.
Tubular specimens of hydrogel were prepared from 10 wt./vol. % solutions of star polymers 3098 and 3385 using 0.7 ml of solution centrifugally cast and irradiated under 6 megarads inside glass tubes of 10 cm length×9 mm lumen. These were tested in an ex vivo shunt model [indium 111 labeled platelets, baboon] with uncoated glass tubes as control. Over a period of 1 hour at a blood flow rate of 100 ml/min., there was no increase of indium count above background for the two hydrogel surfaces, whereas in glass control tubes (no coating) the count more than trebled over background.
Using similar techniques, glass tubes lined with 0.7 ml hydrogels formed from 10 wt./vol. % solutions of linear PEO of 100,000 and 300,000 mol. wt., respectively, under the same dose were prepared. Upon equilibration at 25° C. with pure water, the apparent swelling ratios (final volume:initial volume) were: 1.3, 1.3, 2.8 and 2.0 for Star 3098, Star 3385, PEO 100,000 and PEO 300,000 hydrogels, respectively. Values of 1.3 as compared to 2 or more mean that the star polymer based hydrogels when exposed to blood do not expand to such a degree as to compromise attachment to the surface on which they were cast. The lack of platelet uptake indicates that the star polymers in hydrogel form present a "pure" PEO surface to blood. As such, the DVB cores were shielded from access of plasma proteins by the PEO arms.
Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3951931 *||Sep 9, 1974||Apr 20, 1976||Basf Aktiengesellschaft||Production of polymeric compounds having functional end groups|
|US4280923 *||Dec 18, 1978||Jul 28, 1981||The Dow Chemical Company||Method for fractionating soluble polymers and colloidal particles|
|US4426495 *||Sep 22, 1982||Jan 17, 1984||The General Tire & Rubber Company||Preparation of star polymers|
|US4452892 *||Sep 3, 1981||Jun 5, 1984||United Kingdom Atomic Energy Authority||Immobilization of biologically active material in a hydrogel on a support|
|US4687814 *||Jan 22, 1985||Aug 18, 1987||Centre National De La Recherche Scientifique||Partially hydrophilic, non-ionic crosslinked copolymers and their application to size exclusion chromatography in aqueous media|
|US4713249 *||Jul 4, 1983||Dec 15, 1987||Schroeder Ulf||Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof|
|US4751282 *||Oct 17, 1986||Jun 14, 1988||Sumitomo Chemical Company, Limited||Star block polyol lactam copolymer and process for the production thereof|
|US4794144 *||Sep 30, 1986||Dec 27, 1988||E. I. Du Pont De Nemours And Company||Acrylic star polymers containing multi-functional monomers in the core, made by group transfer polymerization|
|US4840851 *||Sep 27, 1985||Jun 20, 1989||Ytkemiska Institutet||Surface coated article, process and means for the preparation thereof and use thereof|
|US4847328 *||Mar 30, 1987||Jul 11, 1989||E. I. Du Pont De Nemours And Company||Hybrid acrylic star polymers|
|US4863611 *||Apr 30, 1987||Sep 5, 1989||Massachusetts Institute Of Technology||Extracorporeal reactors containing immobilized species|
|US4950709 *||Feb 28, 1989||Aug 21, 1990||Huels Aktiengesellschaft||Process for the preparation of coarse, aqueous plastic dispersions by emulsion polymerizing with a branched polyethylene oxide|
|EP0068509A2 *||Jun 30, 1982||Jan 5, 1983||Toray Industries, Inc.||Antithrombogenic biomedical material|
|EP0263184A1 *||Mar 26, 1987||Apr 13, 1988||Toray Industries, Inc.||Immobilized physiologically active material|
|EP0332261A1 *||Mar 2, 1989||Sep 13, 1989||Stichting voor de Technische Wetenschappen||Method for applying a blood-compatible coating to polyether-urethane moulded articles and the polyether-urethane moulded articles coated in this way|
|1||*||Gnanou, Y. et al., Makromol. Chem. 189:2885 2892 (1988).|
|2||Gnanou, Y. et al., Makromol. Chem. 189:2885-2892 (1988).|
|3||*||Lutz, P. and P. Rempp, Makromol. Chem. 189:1051 1060 (1988).|
|4||Lutz, P. and P. Rempp, Makromol. Chem. 189:1051-1060 (1988).|
|5||*||Merrill, E. W. et al., The 16th Annual Meeting of the Society for Biomaterials, Charleston, SC, May 20 23, 1990.|
|6||Merrill, E. W. et al., The 16th Annual Meeting of the Society for Biomaterials, Charleston, SC, May 20-23, 1990.|
|7||*||Remp, P. et al., American Chemical Society, Polymer Division Symposium, Boston, MA Apr. 1990.|
|8||*||Rempp, P. et al., Advances in Polymer Science 86:145 173 (1988).|
|9||Rempp, P. et al., Advances in Polymer Science 86:145-173 (1988).|
|10||*||Rempp, R. & P. Lutz, Abstracts of the Papers of the American Chemical Society 196: 27 Poly (1988).|
|11||Rempp, R. & P. Lutz, Abstracts of the Papers of the American Chemical Society 196: 27-Poly (1988).|
|12||*||Taromi, F. A. and P. Rempp, Makromol. Chem. 190:1791 1798 (1989).|
|13||Taromi, F. A. and P. Rempp, Makromol. Chem. 190:1791-1798 (1989).|
|14||*||Tay, S. W. et al., Biomaterials 10:11 15 (1989).|
|15||Tay, S. W. et al., Biomaterials 10:11-15 (1989).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5401327 *||Jun 18, 1993||Mar 28, 1995||Wilmington Partners L.P.||Method of treating contact lenses|
|US5446090 *||Nov 12, 1993||Aug 29, 1995||Shearwater Polymers, Inc.||Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules|
|US5468606 *||Jul 31, 1992||Nov 21, 1995||Biostar, Inc.||Devices for detection of an analyte based upon light interference|
|US5470307 *||Mar 16, 1994||Nov 28, 1995||Lindall; Arnold W.||Catheter system for controllably releasing a therapeutic agent at a remote tissue site|
|US5476660 *||Aug 3, 1994||Dec 19, 1995||Lever Brothers Company, Division Of Conopco, Inc.||Deposition of materials to surfaces using zwitterionic carrier particles|
|US5482830 *||Jun 10, 1993||Jan 9, 1996||Biostar, Inc.||Devices and methods for detection of an analyte based upon light interference|
|US5618850 *||Mar 9, 1995||Apr 8, 1997||Focal, Inc.||Hydroxy-acid cosmetics|
|US5711823 *||Feb 21, 1995||Jan 27, 1998||Wilmington Partners L.P.||Method for wetting contact lenses|
|US5739208 *||Jun 7, 1995||Apr 14, 1998||Shearwater Polymers, Inc.||Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules|
|US5741881 *||Nov 25, 1996||Apr 21, 1998||Meadox Medicals, Inc.||Process for preparing covalently bound-heparin containing polyurethane-peo-heparin coating compositions|
|US5830986 *||Oct 28, 1996||Nov 3, 1998||Massachusetts Institute Of Technology||Methods for the synthesis of functionalizable poly(ethylene oxide) star macromolecules|
|US5855618 *||Sep 13, 1996||Jan 5, 1999||Meadox Medicals, Inc.||Polyurethanes grafted with polyethylene oxide chains containing covalently bonded heparin|
|US5868936 *||Jun 20, 1996||Feb 9, 1999||Baxter International Inc.||Affinity membrane system and method of using same|
|US5872086 *||Sep 17, 1997||Feb 16, 1999||Wilmington Partners Lp||Composition for wetting contact lenses|
|US5879688 *||Oct 30, 1996||Mar 9, 1999||Focal, Inc.||Hydroxy-acid cosmetics|
|US5900461 *||Feb 23, 1998||May 4, 1999||Shearwater Polymers, Inc.||Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules|
|US5906828 *||Oct 8, 1997||May 25, 1999||Massachusetts Institute Of Technology||Cell growth substrates with tethered cell growth effector molecules|
|US5912332 *||Jul 26, 1996||Jun 15, 1999||Hybridon, Inc.||Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides|
|US5990237 *||May 20, 1998||Nov 23, 1999||Shearwater Polymers, Inc.||Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines|
|US6045818 *||Nov 25, 1998||Apr 4, 2000||Massachusetts Institute Of Technology||Cell growth substrates with tethered cell growth effector molecules|
|US6096525 *||Nov 26, 1997||Aug 1, 2000||Meadox Medicals, Inc.||Bonding bio-active materials to expanded polytetrafluoroethylene or polyethylene terephthalate via an isocyanate-terminated spacer|
|US6107416 *||Feb 1, 1999||Aug 22, 2000||Scimed Life Systems, Inc.||Polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents|
|US6121027 *||Aug 15, 1997||Sep 19, 2000||Surmodics, Inc.||Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups|
|US6261544||Feb 15, 1999||Jul 17, 2001||Focal, Inc.||Poly(hydroxy acid)/polymer conjugates for skin applications|
|US6306165||Sep 13, 1996||Oct 23, 2001||Meadox Medicals||ePTFE small caliber vascular grafts with significant patency enhancement via a surface coating which contains covalently bonded heparin|
|US6312809 *||Apr 24, 1996||Nov 6, 2001||Sandia Corporation||Dendrimer monolayer films|
|US6338904||Jun 8, 2000||Jan 15, 2002||Scimed Life Systems||Polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents|
|US6491965||Dec 17, 1996||Dec 10, 2002||Hamilton Civic Hospitals Research Development, Inc.||Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates|
|US6509098||Nov 17, 1995||Jan 21, 2003||Massachusetts Institute Of Technology||Poly(ethylene oxide) coated surfaces|
|US6551267||Oct 18, 2000||Apr 22, 2003||Becton, Dickinson And Company||Medical article having blood-contacting surface|
|US6552170||Jun 14, 1994||Apr 22, 2003||Amgen Inc.||PEGylation reagents and compounds formed therewith|
|US6562781||Nov 30, 1995||May 13, 2003||Hamilton Civic Hospitals Research Development Inc.||Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates|
|US6616982||Nov 26, 2002||Sep 9, 2003||Massachusetts Institute Of Technology||Poly(ethylene oxide) coated surfaces|
|US6689165||Mar 30, 2001||Feb 10, 2004||Board Of Supervisors Of Louisana State University And Agricultural And Mechanical College||Surface modifications for enhanced epithelialization|
|US6693083||Feb 12, 2001||Feb 17, 2004||Watson Pharmaceuticals, Inc.||Conjugates targeted to the interleukin-2 receptor|
|US6713568||Aug 19, 1998||Mar 30, 2004||Scimed Life Systems, Inc.||Composition and process for preparing biocompatible polymer coatings|
|US6803069||Jun 20, 2001||Oct 12, 2004||Scimed Life Systems, Inc.||Method for imparting a bio-active coating|
|US6894025||Aug 25, 2003||May 17, 2005||Nektar Therapeutics Al, Corp.||Biologically active molecules having thiol moiety conjugated to polymers containing ethyl sulfone moiety|
|US6985770||Oct 26, 2001||Jan 10, 2006||Biosynergetics, Inc.||Apparatus for the controllable modification of compound concentration in a tube|
|US6989147||Jun 15, 2001||Jan 24, 2006||Amgen Inc.||Truncated soluble tumor necrosis factor type-I and type-II receptors|
|US7008634||Mar 3, 1995||Mar 7, 2006||Massachusetts Institute Of Technology||Cell growth substrates with tethered cell growth effector molecules|
|US7045585||Mar 20, 2002||May 16, 2006||Hamilton Civic Hospital Research Development Inc.||Methods of coating a device using anti-thrombin heparin|
|US7083642 *||Jul 25, 2002||Aug 1, 2006||Avantec Vascular Corporation||Delivery of therapeutic capable agents|
|US7101945||Feb 20, 2002||Sep 5, 2006||Bayer Aktiengesellschaft||Phosphorus-containing polymers for optical signal transducers|
|US7115581 *||May 10, 2002||Oct 3, 2006||La Jolla Pharmaceutical Company||Chemically-defined non-polymeric valency platform molecules and conjugates thereof|
|US7118737||Jul 12, 2001||Oct 10, 2006||Amylin Pharmaceuticals, Inc.||Polymer-modified synthetic proteins|
|US7186810||Aug 29, 2003||Mar 6, 2007||Amgen Inc.||Modified peptides as therapeutic agents|
|US7214366||Apr 22, 2005||May 8, 2007||Nektar Therapeutics Al, Corporation|
|US7255868||Jun 21, 2002||Aug 14, 2007||Dynavax Technologies Corporation||Chimeric immunomodulatory compounds and methods of using the same—I|
|US7351855||Jul 30, 2003||Apr 1, 2008||La Jolla Pharmaceutical Company||Chemically defined non-polymeric valency platform molecules and conjugates thereof|
|US7368505||Jan 5, 2005||May 6, 2008||Massachusetts Institute Of Technology||Graft copolymers|
|US7517705||Aug 21, 2006||Apr 14, 2009||Bayer Aktiengesellschaft||Phosphorus-containing polymers for optical signal transducers|
|US7556858||Sep 30, 2004||Jul 7, 2009||3M Innovative Properties Company||Substrate with attached dendrimers|
|US7616989||Oct 26, 2001||Nov 10, 2009||Biosynergetics, Inc.||Manufacturing methods for an apparatus for the controllable modification of compound concentration in a tube|
|US7625872||Dec 17, 2003||Dec 1, 2009||Dynavax Technologies Corporation||Branched immunomodulatory compounds and methods of using the same|
|US7732587||May 10, 2005||Jun 8, 2010||Amgen Inc.||Nucleic acids encoding truncated soluble tumor necrosis factor|
|US7785610||Dec 23, 2002||Aug 31, 2010||Dynavax Technologies Corporation||Chimeric immunomodulatory compounds and methods of using the same—III|
|US7803769||Oct 25, 2007||Sep 28, 2010||Amgen Inc.||OSK1 peptide analogs and pharmaceutical compositions|
|US7820623||Oct 25, 2007||Oct 26, 2010||Amgen Inc.||Conjugated toxin peptide therapeutic agents|
|US7825093||Oct 25, 2007||Nov 2, 2010||Amgen Inc.||Methods of using OSK1 peptide analogs|
|US7833979||Apr 17, 2006||Nov 16, 2010||Amgen Inc.||Toxin peptide therapeutic agents|
|US7834164||Oct 25, 2007||Nov 16, 2010||Amgen Inc.||DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression|
|US7884083||Aug 12, 2003||Feb 8, 2011||Dynavax Technologies Corporation||Immunomodulatory compositions, methods of making, and methods of use thereof|
|US7910102||Oct 25, 2007||Mar 22, 2011||Amgen Inc.||Methods of using conjugated toxin peptide therapeutic agents|
|US8003115||Aug 10, 2007||Aug 23, 2011||Dynavax Technologies Corporation||Chimeric immunomodulatory compounds and methods of using the same|
|US8034900||Dec 30, 2003||Oct 11, 2011||Amylin Pharmaceuticals, Inc.||Water-soluble thioester and selenoester compounds and methods for making and using the same|
|US8043829||Oct 25, 2007||Oct 25, 2011||Amgen Inc.||DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression|
|US8093039||Apr 8, 2008||Jan 10, 2012||The Trustees Of The Stevens Institute Of Technology||Surfaces differentially adhesive to eukaryotic cells and non-eukaryotic cells|
|US8114418||Jun 21, 2002||Feb 14, 2012||Dynavax Technologies Corporation||Chimeric immunomodulatory compounds and methods of using the same—IV|
|US8222398||Jul 17, 2012||Dynavax Technologies Corporation||Chimeric immunomodulatory compounds and methods of using the same-II|
|US8317760||Oct 31, 2007||Nov 27, 2012||Biosynergetics, Inc.||Apparatus and methods for the controllable modification of compound concentration in a tube|
|US8420779||May 22, 2008||Apr 16, 2013||Amgen Inc.||Compositions and methods for producing bioactive fusion proteins|
|US8597665||Jan 12, 2012||Dec 3, 2013||Dynavax Technologies Corporation||Chimeric immunomodulatory compounds and methods of using the same-IV|
|US8759305||Aug 24, 2005||Jun 24, 2014||Dynavax Technologies Corporation||Methods and compositions for inhibition of innate immune responses and autoimmunity|
|US8795727||Nov 5, 2010||Aug 5, 2014||Spotlight Technology Partners Llc||Fragmented hydrogels|
|US8816000 *||Feb 22, 2010||Aug 26, 2014||Henkel Ag & Co. Kgaa||Multifunctional stellate prepolymer mixtures, production and use and coatings made thereof|
|US8907071||Nov 2, 2010||Dec 9, 2014||Amgen Inc.||Toxin peptide therapeutic agents|
|US8940310||Jun 16, 2011||Jan 27, 2015||Dynavax Technologies Corporation||Methods of treatment using TLR7 and/or TLR9 inhibitors|
|US8962579||Apr 26, 2010||Feb 24, 2015||Dynavax Technologies Corporation||Methods and compositions for inhibition of immune responses and autoimmunity|
|US9028845||Sep 18, 2013||May 12, 2015||Dynavax Technologies Corporation||Chimeric immunomodulatory compounds and methods of using the same-IV|
|US20020082400 *||Dec 29, 2000||Jun 27, 2002||Coutts Stephen M.||Conjugates of T cell epitope deficient immunogen analogs for humoral anergy and chemically defined non-polymeric valency platform molecules|
|US20020114604 *||Feb 20, 2002||Aug 22, 2002||Ingmar Dorn||Phosphorus-containing polymers for optical signal transducers|
|US20030032203 *||Jul 10, 2002||Feb 13, 2003||Sabatini David M.||Small molecule microarrays|
|US20030100487 *||Oct 11, 2002||May 29, 2003||Hamilton Civic Hospitals Res Dev., Inc.||Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates|
|US20030113314 *||Oct 10, 2002||Jun 19, 2003||Hamilton Civic Hospitals Res Dev., Inc.||Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates|
|US20030124705 *||Mar 20, 2002||Jul 3, 2003||Berry Leslie Roy||Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates|
|US20030175731 *||Jun 21, 2002||Sep 18, 2003||Fearon Karen L.||Chimeric immunomodulatory compounds and methods of using the same - I|
|US20030190304 *||Mar 27, 2003||Oct 9, 2003||Amgen Inc.||Pegylation reagents and compounds formed therewith|
|US20030191291 *||Jul 12, 2001||Oct 9, 2003||Kochendoerfer Gerd G.||Synthetic erythropoiesis stimulating proteins|
|US20030199466 *||Jun 21, 2002||Oct 23, 2003||Fearon Karen L.||Chimeric immunomodulatory compounds and methods of using the same - ll|
|US20040037801 *||Aug 25, 2003||Feb 26, 2004||Harris J. Milton|
|US20040077835 *||Jul 12, 2001||Apr 22, 2004||Robin Offord||Chemokine receptor modulators, production and use|
|US20040087778 *||Aug 29, 2003||May 6, 2004||Amgen Inc.||Modified peptides as therapeutic agents|
|US20040121451 *||Mar 15, 2002||Jun 24, 2004||Niko Moritz||Treatment of sols, gels and mixtures thereof|
|US20040136948 *||Dec 17, 2003||Jul 15, 2004||Dynavax Technologies Corporation||Branched immunomodulatory compounds and methods of using the same|
|US20040137039 *||Jul 22, 2003||Jul 15, 2004||Trustees Of Stevens Institute Of Technology||Methods for controlled release of molecules from layered polymer films|
|US20040224366 *||Jun 14, 2004||Nov 11, 2004||Jones David S.||Valency platform molecules comprising aminooxy groups|
|US20050008828 *||Jul 24, 2003||Jan 13, 2005||Trustees Of Stevens Institute Of Technology||Patterned polymer microgel and method of forming same|
|US20050089970 *||Jul 12, 2001||Apr 28, 2005||Bradburne James A.||Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use|
|US20050163714 *||Sep 30, 2004||Jul 28, 2005||Sukhishvili Svetlana A.||Capsules of multilayered neutral polymer films associated by hydrogen bonding|
|US20050209416 *||Apr 22, 2005||Sep 22, 2005||Nektar Therapeutics Al, Corporation|
|US20050250696 *||May 10, 2005||Nov 10, 2005||Fisher Eric F||Truncated soluble tumor necrosis factor type-I and type-II receptors|
|US20060014003 *||May 31, 2005||Jan 19, 2006||Libera Matthew R||Functional nano-scale gels|
|US20060068204 *||Sep 30, 2004||Mar 30, 2006||3M Innovative Properties Company||Substrate with attached dendrimers|
|US20060089461 *||Jan 5, 2005||Apr 27, 2006||Mayes Anne M||Graft copolymers|
|US20060173159 *||Dec 30, 2003||Aug 3, 2006||Miranda Leslie P||Water-soluble thioester and selenoester compounds and methods for making and using the same|
|US20060193869 *||Dec 16, 2005||Aug 31, 2006||Franck Barrat||Methods and compositions for induction or promotion of immune tolerance|
|US20060233747 *||Jun 5, 2006||Oct 19, 2006||Amylin Pharmaceuticals, Inc.||Polymer-modified synthetic proteins|
|US20060287453 *||Aug 21, 2006||Dec 21, 2006||Bayer Aktiengesellschaft||Phosphorus-containing polymers for optical signal transducers|
|US20070071764 *||Apr 17, 2006||Mar 29, 2007||Sullivan John K||Toxin peptide therapeutic agents|
|US20070238678 *||Aug 24, 2005||Oct 11, 2007||Franck Barrat||Methods and compositions for inhibition of innate immune responses and autoimmunity|
|US20080255677 *||Apr 8, 2008||Oct 16, 2008||Libera Matthew R||Surfaces differentially adhesive to bacteria and eukaryotic cells|
|US20080268013 *||Feb 10, 2006||Oct 30, 2008||Emory University||Polyethylene Oxide Polymers Including Anti-Inflammatory Glycodendrons|
|US20090252703 *||Oct 12, 2007||Oct 8, 2009||Gegg Jr Colin V||Use of alcohol co-solvents to improve pegylation reaction yields|
|US20090281028 *||Nov 12, 2009||Sullivan John K||OSK1 peptide analogs and pharmaceutical compositions|
|US20090299044 *||Oct 25, 2007||Dec 3, 2009||Sullivan John K||DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression|
|US20090305399 *||Dec 10, 2009||Sullivan John K||DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression|
|US20100209613 *||Feb 22, 2010||Aug 19, 2010||Haitao Rong||Multifunctional stellate prepolymer mixtures, production and use and coatings made thereof|
|US20110003885 *||Jan 6, 2011||Dynavax Technologies Corporation||Methods and compositions for inhibition of immune responses and autoimmunity|
|US20110045587 *||Feb 24, 2011||Amegen Inc.||Toxin peptide therapeutic agents|
|US20110123561 *||May 26, 2011||Dynavax Technologies Corporation||Methods and compositions for induction or promotion of immune tolerance|
|US20110136727 *||Jun 9, 2011||Sergei Svarovsky||Compositions and methods for rapid selection of pathogen binding agents|
|DE10106546A1 *||Feb 13, 2001||Aug 22, 2002||Ethicon Gmbh||Verfahren zum Herstellen eines medizinischen Implantats|
|EP1199104A2 *||Oct 1, 2001||Apr 24, 2002||Becton, Dickinson and Company||Medical article having blood-contacting surface|
|EP1577670A2 *||Aug 11, 1998||Sep 21, 2005||SurModics, Inc.||Latent reactive polymers with biologically active moieties|
|EP2279756A2||Mar 31, 2006||Feb 2, 2011||Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A.||Method for shielding functional sites or epitopes on proteins|
|EP2305693A1||Aug 24, 2005||Apr 6, 2011||Dynavax Technologies Corporation||Methods and compositions for inhibition of innate immune responses and autoimmunity|
|EP2314320A2||Mar 31, 2006||Apr 27, 2011||Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A.||Method for shielding functional sites or epitopes on proteins|
|EP2361980A1||Oct 27, 2008||Aug 31, 2011||Dynavax Technologies Corporation||Methods and compositions for inhibition of immune responses and autoimmunity|
|EP2423335A2||Jun 21, 2002||Feb 29, 2012||Dynavax Technologies Corporation||Chimeric immunomodulatory compounds and methods of using the same|
|EP2425860A1||Aug 11, 2006||Mar 7, 2012||Amgen Inc.||Modified Fc molecules|
|EP2548967A2||Sep 19, 2007||Jan 23, 2013||The Regents of The University of California||Aldehyde tags, uses thereof in site-specific protein modification|
|EP2738257A1||May 22, 2008||Jun 4, 2014||Amgen Inc.||Compositions and methods for producing bioactive fusion proteins|
|WO1995024939A1 *||Mar 16, 1995||Sep 21, 1995||Arnold W Lindall||Catheter system for controllably releasing a therapeutic agent at a remote tissue site|
|WO1997039041A1 *||Apr 16, 1997||Oct 23, 1997||Texas A & M Univ Sys||Dendrimer monolayer films|
|WO1998018494A1 *||Oct 27, 1997||May 7, 1998||Massachusetts Inst Technology||Methods for the synthesis of functionalizable poly(ethylene oxide) star macromolecules|
|WO1999008514A1 *||Aug 20, 1998||Feb 25, 1999||Lxr Biotechnology Inc||Compositions containing polyethylene glycol and uses thereof|
|WO1999016318A1 *||Sep 24, 1998||Apr 8, 1999||Uab Research Foundation||Reduced antigenic cells and uses therefor|
|WO1999053955A1 *||Apr 21, 1999||Oct 28, 1999||Desmos Inc||Creation of bioactive surfaces through selective adsorption|
|WO2002074354A1 *||Mar 15, 2002||Sep 26, 2002||Delsitech Oy||Treatment of sols, gels, mixtures or composites of sols and gels, and/or sol-gel derived materials|
|WO2003046144A2 *||Nov 26, 2002||Jun 5, 2003||Molecular Reflections Inc||Microscale immobilization of molecules using a hydrogel and methods of use thereof|
|WO2003056293A2 *||Jul 10, 2002||Jul 10, 2003||Massachusetts Inst Technology||Small molecule microarrays|
|WO2004005402A1 *||Jul 3, 2003||Jan 15, 2004||Metin Acar||Graft copolymers|
|WO2004061094A1||Dec 30, 2003||Jul 22, 2004||Gryphon Therapeutics Inc||Water-soluble thioester and selenoester compounds and methods for making and using the same|
|WO2006028742A2||Aug 24, 2005||Mar 16, 2006||Dynavax Tech Corp||Methods and conpositions for inhibition of innate immune responses and autoimmunity|
|WO2012125973A2||Mar 16, 2012||Sep 20, 2012||Amgen Inc.||Potent and selective inhibitors of nav1.3 and nav1.7|
|WO2013006706A1||Jul 5, 2012||Jan 10, 2013||Bioasis Technologies Inc.||P97-antibody conjugates and methods of use|
|WO2014022515A1||Jul 31, 2013||Feb 6, 2014||Bioasis Technologies, Inc.||Dephosphorylated lysosomal storage disease proteins and methods of use thereof|
|WO2014052931A1||Sep 27, 2013||Apr 3, 2014||Dynavax Technologies Corporation||Human toll-like receptor inhibitors and methods of use thereof|
|WO2014063757A1||Oct 26, 2012||May 1, 2014||Universiteit Leiden||Delivery methods|
|WO2014099984A1||Dec 17, 2013||Jun 26, 2014||Amgen Inc.||Apj receptor agonists and uses thereof|
|WO2014160438A1||Mar 13, 2014||Oct 2, 2014||Bioasis Technologies Inc.||Fragments of p97 and uses thereof|
|WO2014165277A2||Mar 12, 2014||Oct 9, 2014||Amgen Inc.||POTENT AND SELECTIVE INHIBITORS OF Nav1.7|
|WO2015031673A2||Aug 28, 2014||Mar 5, 2015||Bioasis Technologies Inc.||Cns-targeted conjugates having modified fc regions and methods of use thereof|
|WO2015191781A2||Jun 10, 2015||Dec 17, 2015||Amgen Inc.||Apelin polypeptides|
|U.S. Classification||623/3.1, 427/533, 427/2.25, 427/2.28, 436/512, 427/352, 436/547, 436/518, 435/975, 427/337, 606/194, 427/2.3, 436/828, 427/2.24|
|International Classification||B01J20/26, B01J20/32, A61L33/06, A61K39/00, C08J7/04, A61L33/00, B01D67/00, C07K1/22, A61K39/12, B01D71/28, A61K47/48, G02B1/04, G01N33/545, A61K39/395|
|Cooperative Classification||B01J20/3287, B01J20/3219, B01J20/321, B01J20/3272, B01J20/3282, Y10S436/828, Y10S435/975, A61L33/0064, C07K1/22, A61K47/48992, B01D67/0088, A61L33/0029, B01D67/0093, A61L33/068, G02B1/043, A61K47/48784, G01N33/545, B01D2323/34, B01D2323/30|
|European Classification||A61L33/00H2F, A61L33/06D, G02B1/04B2, A61L33/00H7, B01J20/32, G01N33/545, B01D67/00R18, A61K47/48W4, A61K47/48W26, C07K1/22, B01D67/00R14|
|Apr 9, 1990||AS||Assignment|
Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:MERRILL, EDWARD W.;REEL/FRAME:005289/0981
Effective date: 19900330
|May 20, 1996||FPAY||Fee payment|
Year of fee payment: 4
|Jun 27, 2000||SULP||Surcharge for late payment|
|Jun 27, 2000||FPAY||Fee payment|
Year of fee payment: 8
|Jun 30, 2004||REMI||Maintenance fee reminder mailed|
|Aug 20, 2004||FPAY||Fee payment|
Year of fee payment: 12
|Aug 20, 2004||SULP||Surcharge for late payment|
Year of fee payment: 11